Risk of second primary malignancies after definitive treatment for esophageal cancer: A competing risk analysis
Seiichiro Mitani(Kindai University Hospital), Kei Muro(Aichi Cancer Center), Yukiya Narita(Aichi Cancer Center), Masahiro Tajika(Aichi Cancer Center), Hideaki Bando(Aichi Cancer Center), Shigenori Kadowaki(Aichi Cancer Center), Takeshi Kodaira(Aichi Cancer Center), Sachiyo Oonishi(Aichi Cancer Center), Yutaro Koide(Nagoya University Hospital), Isao Oze(Aichi Cancer Center), Tsutomu Tanaka(Aichi Cancer Center), Tetsuya Abe(Aichi Cancer Center), Yutaka Hirayama(Aichi Cancer Center), Toshiki Masuishi(Aichi Cancer Center)
Cited by 23
Related Papers
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2017|2.5k
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2019|2k
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2018|1.3k
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
|Journal of Clinical Oncology|2020|1.2k
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2011|713